Cell Therapeutics, Inc. (CTI) Announces Resignation of Independent Auditor.
PR Newswire Europe, September, 2005
SEATTLE, September 2 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ: CTIC; Nuovo Mercato) announced today that Grant Thornton resigned effective August 31, 2005 as the Company's independent auditor. There were no disagreements between CTI and Grant Thornton on any matter of accounting principles or practice, financial disclosure, or audit procedures.
"We've had a good relationship with Grant Thornton and I am working with the Audit Committee to engage a new audit firm as soon as possible," stated Louis A. Bianco, Chief Financial Officer of CTI.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer...
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- LIFO vs. FIFO: a return to the basics
- Design a commission plan that drives sales - Sales Commissions
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
